Please assess the completion status of the following clinical trial:

Trial Title: InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation~2. Patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or)~3. Patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or)~4. Patients who received CAR-T cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 \& 7) (and/or)~5. Patients receiving hormonal therapy for cancer (and/or)~6. Patients who have undergone surgery or radiotherapy for cancer within the past 6 months~7. Patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get COVID pneumonia in the interim (Incl. Criteria 11)~8. Men and women aged ≥ 25 - 80 (included) years of age~9. Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline .~   From this time point the investigator may choose to further postpone the commencement of IL-7 (CYT107) treatment according to patient's clinical status.~10. Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4L per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated/ventilated for respiratory failure~11. Confirmed infection with COVID-19 by any acceptable test available/utilized at each site~12. Willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure~Exclusion Criteria:~1. Pregnancy or breast feeding;~2. ALT and/or AST \> 5 x ULN~3. Known, active auto-immune disease;~4. Patients with a history of lymphoid malignancy~5. Patients with any malignancy that is present at time of enrollment where treating physician expects life expectancy due to the underlying malignancy to be less than 6 months~6. Patients who received CAR-T cell therapy within the past 30 days or with unresolved cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)~7. Patients with unresolved grade \> 2 toxicities from prior chemotherapy, immunotherapy, or CAR-T cell therapy~8. Patients with past history of Solid Organ transplant.~9. Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load.~10. Hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours~11. Patients with a mechanical ventilation support ≥ 7 days~12. Patients with chronic kidney dialysis~13. Patients with a SOFA score ≥ 9 at baseline~14. Patients with a BMI \> 40~15. Patients showing an increase of the NEWS2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration)~16. Patients with hospital admission Rockwood Clinical Frailty Scale ≥ 6. (assessed as patient or proxy 4-week recall of chronic health and frailty status prior to COVID infection)~11. Patients under guardianship

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CYT107 Treatment (Type: EXPERIMENTAL): Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
- Saline control (Type: PLACEBO_COMPARATOR): Intramuscular (IM) placebo (normal saline) at the same frequency

Based on this trial design, predict the completion outcome and termination type (if applicable).